Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice

Restricted access

Substantial research efforts have focused on methods of treating and preventing oxaliplatin-associated neuropathy, the dose-limiting toxicity associated with this drug. Administration of intravenous calcium and magnesium (CaMg) before and after oxaliplatin has been the most studied approach to preventing oxaliplatin-induced neuropathy. Although early reports demonstrated potential benefit, subsequent larger trials failed to confirm the efficacy of CaMg in preventing this adverse effect. This article explores how accumulating evidence for and against the use of CaMg for preventing oxaliplatin-induced neuropathy has impacted clinical practice.

Correspondence: Charles L. Loprinzi, MD, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905. E-mail: cloprinzi@mayo.edu
  • 1.

    GrolleauFGamelinLBoisdron-CelleM. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol2001;85:22932297.

    • Search Google Scholar
    • Export Citation
  • 2.

    GamelinEGamelinLDelvaR. Prevention of oxaliplatin peripheral sensory neuropathy by Ca+ gluconate/Mg+ chloride infusions: a retrospective study [abstract]. Proc Am Soc Clin Oncol2002;21:157a. Abstract 624.

    • Search Google Scholar
    • Export Citation
  • 3.

    GamelinLBoisdron-CelleMDelvaR. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res2004;10:40554061.

    • Search Google Scholar
    • Export Citation
  • 4.

    HochsterHSGrotheyAChildsBH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol2007;25:40284029.

    • Search Google Scholar
    • Export Citation
  • 5.

    GamelinLBoisdron-CelleMMorelA. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol2008;26:11881189; author reply 1189–1190.

    • Search Google Scholar
    • Export Citation
  • 6.

    GrotheyAHartLLRowlandKM. Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): final results of the phase III CONcePT trial [abstract]. J Clin Oncol2008;26(Suppl):Abstract 4010.

    • Search Google Scholar
    • Export Citation
  • 7.

    NikcevichDAGrotheyASloanJA. Intravenous calcium and magnesium prevents oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: results of a phase III placebo-controlled, double-blind trial (N04C7) [abstract]. J Clin Oncol2008;26(Suppl):Abstract 4009.

    • Search Google Scholar
    • Export Citation
  • 8.

    GrotheyANikcevichDASloanJA. Evaluation of the effect of intravenous calcium and magnesium (CaMg) on chronic and acute neurotoxicity associated with oxaliplatin: results from a placebo-controlled phase III trial. J Clin Oncol2009;27(Suppl):Abstract 4025.

    • Search Google Scholar
    • Export Citation
  • 9.

    GrotheyANikcevichDASloanJA. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol2011;29:421427. Published online ahead of print December 28 2010.

    • Search Google Scholar
    • Export Citation
  • 10.

    LoprinziCLQinRDakhilSR. Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: an alliance for clinical trials in oncology study. J Clin Oncol2013;31(Suppl):Abstract 3501.

    • Search Google Scholar
    • Export Citation
  • 11.

    LoprinziCLQinRDakhilSR. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol2014;32:9971005. Published online ahead of print December 3 2013.

    • Search Google Scholar
    • Export Citation
  • 12.

    ChayWYTanSHLoYL. Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy. Asia Pac J Clin Oncol2010;6:270277.

    • Search Google Scholar
    • Export Citation
  • 13.

    DongMXingPYLiuP. Assessment of the protective effect of calcium-magnesium infusion and glutathione on oxaliplatin-induced neurotoxicity [in Chinese]. Zhonghua zhong Liu Za Zhi2010;32:208211.

    • Search Google Scholar
    • Export Citation
  • 14.

    IshibashiKOkadaNMiyazakiT. Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study. Int J Clin Oncol2010;15:8287.

    • Search Google Scholar
    • Export Citation
  • 15.

    WallacePJShahNDDennenT. Optum Labs: building a novel node in the learning health care system. Health Aff (Millwood)2014;33:11871194.

    • Search Google Scholar
    • Export Citation
  • 16.

    GrotheyASugrueMMPurdieDM. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol2008;26:53265334.

    • Search Google Scholar
    • Export Citation
  • 17.

    BennounaJSastreJArnoldD. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol2013;14:2937.

    • Search Google Scholar
    • Export Citation
  • 18.

    BerryDAUenoNTJohnsonMM. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol2011;29:32143223.

    • Search Google Scholar
    • Export Citation
  • 19.

    SchragDChungKYFlombaumC. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst2005;97:12211224.

  • 20.

    FakihMGWildingGLombardoJ. Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin Colorectal Cancer2006;6:152156.

  • 21.

    TejparSPiessevauxHClaesK. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol2007;8:387394.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 164 164 18
PDF Downloads 18 18 4
EPUB Downloads 0 0 0